Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion
The deal expands the pharmaceutical company’s portfolio of cancer drugs. Source link
Amgen's Deal for Horizon Therapeutics Clears Key Hurdle
The Federal Trade Commission said it had agreed to end its legal challenge of the $27.8 billion deal. The pact also dismisses the antitrust claims
FTC Pauses Challenge to Amgen's $27.8 Billion Deal for Horizon Therapeutics
The move gives the agency time to weigh a settlement that would allow the deal to close with conditions. Source link
Canaccord Genuity Initiates Coverage of Intellia Therapeutics (NTLA) with Buy Recommendation
Fintel reports that on April 13, 2023, Canaccord Genuity initiated coverage of Intellia Therapeutics (NASDAQ:NTLA) with a Buy recommendation. Analyst Price Forecast Suggests 181.05% Upside
Morgan Stanley Maintains Axsome Therapeutics (AXSM) Equal-Weight Recommendation
Fintel reports that on April 12, 2023, Morgan Stanley maintained coverage of Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 78.83% Upside
July 21st Options Now Available For Viking Therapeutics (VKTX)
Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options become available today, for the July 21st expiration. One of the key inputs that goes
Unusual Call Option Trade in Seelos Therapeutics (SEEL) Worth $17.57K
On April 6, 2023 at 10:11:23 ET an unusually large $17.57K block of Call contracts in Seelos Therapeutics (SEEL) was sold, with a strike price
JP Morgan Maintains Relay Therapeutics (RLAY) Overweight Recommendation
On April 5, 2023, JP Morgan maintained coverage of Relay Therapeutics with a Overweight recommendation. Analyst Price Forecast Suggests 103.68% Upside As of March 30,
HC Wainwright & Co. Maintains Allogene Therapeutics (ALLO) Buy Recommendation
On April 4, 2023, HC Wainwright & Co. maintained coverage of Allogene Therapeutics with a Buy recommendation. Analyst Price Forecast Suggests 294.83% Upside As of
Y-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains?
Y-mAbs Therapeutics, Inc. YMAB shares soared 13.8% in the last trading session to close at $5.70. The move was backed by solid volume with far
